Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

742
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
742
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

673
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
673
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

481
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
481
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

401
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
401
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

2.6K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.6K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.6K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.6K
  1. ホーム
  3. 慢性腎臓病の患者におけるサクビトリル/ヴァルサタンとアーベサタンの効果
  1. ホーム
  3. 慢性腎臓病の患者におけるサクビトリル/ヴァルサタンとアーベサタンの効果

関連する実験動画

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.8K

慢性腎臓病の患者におけるサクビトリル/ヴァルサタンとアーベサタンの効果

Richard Haynes1,2, Parminder K Judge1,2, Natalie Staplin2

  • 1Medical Research Council Population Health Research Unit (R.H., P.K.J., W.G.H., B.C.S., M.H., M.J.L., C.B.), University of Oxford, UK.

Circulation
|July 14, 2018

PubMed で要約を見る

まとめ
この要約は機械生成です。

サクビトリル/ バルサータンは,慢性腎臓病患者の腎臓機能に,イルベサタンと比較して,差異を示さなかった. しかし,血圧と心臓のバイオマーカーを効果的に低下させました.

キーワード:
慢性腎臓疾患ネプリリシン抑制レニン・アニオテンシン系

さらに関連する動画

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

1.6K
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

10.5K

関連する実験動画

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.8K
Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

1.6K
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

10.5K

科学分野:

  • 心臓病科
  • 腎臓科
  • 薬理学について

背景:

  • サクビトリル/ バルサタンは,心不全における心血管死亡率を減少させることが知られている.
  • 中度重度の慢性腎臓病 (CKD) の患者における腎臓機能と心臓のバイオマーカーへの影響は,以前は知られていなかった.

研究 の 目的:

  • 中度重症から重症のCKD患者の腎機能と心臓のバイオマーカーに対するサクビトリル/ バルサタンの効果を評価する.
  • この患者群でサクビトリル/ バルサタンとイルベサタンを比較する.

主な方法:

  • イギリスのHARP- III試験はランダム化され,ダブルブラインド試験で,414人の参加者が参加し,推定グルメルフィルタレーション率 (GFR) は20〜60ml/ min/ 1. 73m2であった.
  • 参加者にはサクビトリル/ヴァルサタンまたはイルベサタンが割り当てられ,12ヶ月後にGFRが測定された.

主要な成果:

  • サクビトリル/ バルサタンとイルベサタン群の間で12ヶ月で測定されたGFRの有意な差は認められなかった (29. 8 vs 29. 9 mL/ min/ 1. 73 m2).
  • サクビトリル/ バルサータンは,シストリックとダイアストリックの血圧を有意に低下させ,トロポニンIとN末端プロホルモン脳ナトリウレチンペプチドのレベルを低下させた.
  • 尿中のアルブミン:クレアチニンの比率や有害事象の発生率は有意な差異はなかった.

結論:

  • サクビトリル/ バルサータンは,慢性腎臓病患者の腎臓機能とアルブミヌリアに12ヶ月間にわたってイルベサタンと同様の効果を示しています.
  • サクビトリル/ バルサータンは,この集団において,血圧の低下と心臓バイオマーカーの低下という追加の利点を提供します.